Sytalizumab

Primary objective To evaluate the safety and tolerability of cedarizumab in patients with advanced solid tumors; Secondary objective To determine the effectiveness of cedarizumab in patients with advanced solid tumors and recommend solid tumor indications for later clinical trials. To evaluate the pharmacokinetic characteristics of cedarizumab. To evaluate the immunogenicity of cedarizumab. Exploratory objective To explore the anti-tumor activity of cedarizumab using the iRECIST standard (2017); To explore the pharmacodynamic characteristics of cedarizumab; To explore the relationship between relevant biomarkers and clinical efficacy.